Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer.

ABSTRACT:

Purpose

Neoadjuvant chemo-immunotherapy for high-risk triple-negative breast cancer (TNBC) has been shown to reduce the risk of recurrence and improve survival. However, the prognosis for patients with metastatic TNBC remains poor, especially for those with an early recurrence, who represent an urgent unmet need. Defining the most common timing of recurrences after chemo-immunotherapy is crucial for shaping the design of future clinical trials.

Experimental design

We analyzed five clinical trials of neoadjuvant chemo-immunotherapy in early-stage TNBC to quantify the contribution of early recurrences (within 24 months from randomization) to the overall risk of relapse. Event-free survival data were extracted from Kaplan-Meier curves using PlotDigitizer. Events were evaluated

SUBMITTER: Licata L 

PROVIDER: S-EPMC12434393 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature